- Research Article
- Open Access
Cholinergic Anti-Inflammatory Pathway Activity and High Mobility Group Box-1 (HMGB1) Serum Levels in Patients with Rheumatoid Arthritis
- Richard S. Goldstein1, 2Email author,
- Annette Bruchfeld1, 3,
- Lihong Yang1,
- Abdul R. Qureshi3,
- Margot Gallowitsch-Puerta1,
- Nirav B. Patel1,
- Brett J. Huston1,
- Sangeeta Chavan1,
- Mauricio Rosas-Ballina1,
- Peter K. Gregersen1,
- Christopher J. Czura1,
- Richard P. Sloan4,
- Andrew E. Sama1, 2 and
- Kevin J. Tracey1
© Feinstein Institute for Medical Research 2007
- Received: 7 December 2006
- Accepted: 29 December 2006
- Published: 1 March 2007
High Mobility Group Box-1 (HMGB1) is a cytokine implicated in the pathogenesis of rheumatoid arthritis (RA) and other inflammatory diseases. The cholinergic anti-inflammatory pathway, a vagus nerve-dependent mechanism, inhibits HMGB1 release in experimental disease models. Here, we examine the relationship between vagus nerve activity and HMGB1 in patients with RA. We compared RR interval variability, an index of cardiac vagal modulation, HMGB1 and hsCRP serum levels, and disease activity scores in thirteen RA patients and eleven age- and sex-matched controls. In RA patients, serum levels of HMGB1 and hsCRP were elevated as compared with controls (HMGB1 = 71 ng/mL [45–99] vs. 18 ng/mL [0–40], P < 0.0001; hsCRP = 14.5 mg/L [0.7–59] vs. 1 mg/L [0.4–2.9], P < 0.001). RR interval variability in RA patients was significantly decreased as compared with controls (HF = 38 msec2 [14–80] vs. 288 msec2 [38–364], P < 0.0001; rMSSD = 20.9 ± 9.79 msec, 52.6 ± 35.3 msec, P < 0.01). HMGB1 levels and RR interval variability were significantly related (rho = −0.49, P < 0.01). HMGB1 serum levels significantly correlated with disease activity scores (DAS-28) in patients with RA (P = 0.004). The study design does not enable a determination of causality, but the results are consistent with the hypothesis that decreased cholinergic anti-inflammatory pathway activity is associated with increased HMGB1 levels in patients with RA.
Rheumatoid arthritis (RA), a chronic autoimmune destructive polyarthropathy, has a worldwide prevalence of 0.5–1%, and an incidence of three cases per 10,000 persons annually (1–3). Affected individuals have significantly diminished quality of life and a three to ten year decrease in life expectancy (4). Over-expression of cytokines mediates tissue injury and drugs that decrease the activity of TNF or IL-1 have improved the lives of RA patients significantly. High mobility group box-1 (HMGB1), a recently identified proinflammatory cytokine, has been implicated in the pathogenesis of arthritis (5–10). HMGB1 expression is increased in the synovium of patients with RA and in experimental animal models of collagen and adjuvant-induced arthritis (6). Anti-HMGB1 antibodies confer significant protection against the development of experimental arthritis in animals, but little is known about mechanisms that regulate HMGB1 release in this disease (5–7).
The cholinergic anti-inflammatory pathway is a neural mechanism that inhibits the expression of HMGB1 and other cytokines (11–16). Signals transmitted via the vagus nerve, the principal nerve of the parasympathetic nervous system, significantly attenuate the release of HMGB1 and other cytokines in animal models of inflammation (11–16). Here we considered whether decreased activity in the cholinergic anti-inflammatory pathway might occur in patients with RA. The results indicate that depressed levels of vagus nerve activity correlate with elevated levels of HMGB1.
This prospective observational study protocol was approved by the General Clinical Research Advisory Committee (GAC) and the North Shore-LIJ Institutional Review Board. Patients were recruited from the North American Rheumatoid Arthritis Consortium (NARAC) and by affiliated Rheumatology clinic referrals. Informed consent was explained and subsequently obtained in all subjects. The total number of subjects enrolled was twenty-four (RA patients = 13, healthy volunteers = 11). Patients had an established diagnosis of RA according to the ACR criteria (17). None of the RA patients had a history of smoking. Two RA patients had hypertension controlled with medication. No other cardiovascular risk factors were identified in the RA subjects. Healthy volunteers were age- and sex-matched and were free of cardiovascular risk factors.
Disease Duration (years)
Rheumatoid-factor positive (%)
C-reactive protein (mg/L)
Disease activity score-28 (mean ± SD)
4.5 ± 0.94
Calcium Channel Antagonists
TNF receptor Blockers
RR Interval Variability Measurements
Subjects were instructed not to consume food or caffeine prior to arrival at the North Shore-LIJ General Clinical Research Center (GCRC) between 0700–1000. RR interval variability was measured in each subject by placing three ECG electrodes on the anterior chest wall and a respiratory sensor around the circumference of the abdomen. After a five min rest in a dimly lit room, RR interval variability was recorded for a twenty min interval. Subjects were awake in the seated position in a reclining chair, and although the depth and rate of breathing was not controlled, the observed respiratory rates were in the high frequency range (ten to twenty breaths per minute). Ectopic beats and artifacts on the ECG’s were edited by averaging, splitting, or adding consecutive beats. The total amount of editing for each patient was less than one percent of the recording duration.
RR interval variability measurements were computed using CardioPro 2.0 software (Thought Technology Ltd., Canada). Fast-Fourier analysis was used to generate frequency domain measures. For each five min epoch, HF power (0.15–0.40 Hz), LF power (0.04–0.15 Hz), the LF/HF ratio and rMSSD were computed. This analysis adhered to the standards developed by the Task Force of the European Society of Cardiology and the North American Society of Pacing and Electro-physiology (19). The low frequency to high frequency ratio (LF/HF), a measure of sympathovagal balance, and rMSSD, a reflection of vagal nerve activity, were calculated. Absolute values of frequency domain analysis were calculated from normalized data (i.e. HF = HFN × [Total Power-VLF]/100, LF = LFN × [Total Power-VLF]/100). Means of all 4 epochs were calculated for each subject.
Whole blood was collected in non-heparinized tubes and allowed to clot at room temperature (22–24°C) for 2 h. Tubes were centrifuged at 2000g for ten min and supernatant collected. Serum was aliquoted into microfuge tubes and stored at −80°C. HMGB1 levels were measured by Western immunoblotting analysis. In brief, sera samples were thawed on ice and microfuged for ten min at 9700g. The supernatant (100–200 µL) was ultrafiltered with Microcon YM-100 filters (Millpore, Billerica, MA, USA). Filtrate was transferred to a new tube, mixed with 5X Laemmli Sample Buffer (BioRad, Hercules, CA, USA), heated at 95°C for five min and spun down at 8160g for five min in tabletop microfuge. 12.5 µLof heated sample (10 µLserum per lane) was fractionated through 1020% Tris-HCL acrylamide gels (BioRad) and transferred to preactivated polyvinyline fluoride (PVDF) membrane (BioRad). PVDF membrane was pre-activated with methanol, rinsed and equilibrated in Tris/Glycine/20% Methanol transfer buffer. After transfer, the membrane was rinsed briefly with wash buffer (0.2% Tween 20 in PBS) and incubated for 1 h in blocking buffer (5% non-fat dry milk in wash buffer). The membrane was probed overnight at 4°C with purified IgG from anti-HMGB1 antiserum (2 µg/mL in 1% non-fat dry milk in wash buffer). The membrane was washed two times at ten min intervals in wash buffer and incubated with peroxidase conjugated anti-rabbit secondary antibody (Amersham Biosciences, Piscataway, NJ, USA, 1:7500 dilution) for 1 h. The membrane was washed three times at fifteen min intervals in wash buffer followed by five min in 1X PBS. After rinsing the membrane in distilled water, the signals were visualized using ECL Western blotting detection reagents (Amersham Biosciences). Equal volumes of ECL A and B were mixed and added to the PVDF membrane and incubated for 1 min. Excess reagent was removed by blotting the edge of the PVDF membrane on a paper towel. PVDF membrane was then exposed to Hyperfilm (Amersham Biosciences). Autoradiograph films were scanned and densitometric analyses performed using Quantity One software (BioRad) and Microsoft Excel. The levels of HMGB1 were determined by reference to standard curves generated with purified HMGB1.
High sensitivity CRP serum analysis was performed using a Hitachi 917 Analyzer (Roche Diagnostics, Indianapolis, IN, USA). The standard reference range for hsCRP is 0.0–3.0 mg/L.
Role of the Funding Source
The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing of the study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the manuscript for publication.
All values are expressed as median (range), unless otherwise indicated. A P value < 0.05 was considered to be statistically significant. Comparisons between two groups were assessed for continuous variables with the Wilcoxon test. Differences among three groups were analyzed by analysis of variance (ANOVA) using the Kruskal-Wallis test. Spearman’s rank correlation was used to determine correlations between continuous variables. Fisher’s Exact test was used for comparing categorical variables between the two groups. The statistical analysis was performed using statistical software SAS version 9.1.4 (SAS Campus Drive, Cary, NC, USA). Covariant analysis was performed using respiratory rates for the established effect that respiration has on HF power (21).
Patient medications and co-morbidities
Avg = 52.7 Median=52
TNF-alpha blocker p ]Methotrexate Prednisone
TNF-alpha blocker Methotrexate Folic Acid
TNF-alpha blocker Methotrexate Folic Acid Hydroxychloroquine NSAIDS
TNF-alpha blocker Prednisone
TNF-alpha blocker Methotrexate Folic Acid Prednisone
Methotrexate Prednisone NSAIDs
Sulfasalazine Methotrexate Folic Acid Prednisone
TNF-alpha blocker Methotrexate Folic Acid Prednisone
HMGB1, CRP, and Vagus Nerve Activity
Correlation of Vagus Nerve Activity, HMGB1 Levels, and Disease Activity
Serum HMGB1 levels were significantly correlated to HF power (rho = −0.49, P < 0.01). Causality cannot be determined in this study and it is theoretically possible that advanced inflammation and subsequent damage cause the observed decrease in vagus nerve activity. If decreased vagus nerve activity occurs as a result of damage, however, then vagus nerve activity should be less in patients with severe disease as compared with mild disease. On the contrary, we observed that vagus nerve activity is significantly decreased even in patients with mild disease (Figure 3a). This observation is consistent with the hypothesis that decreased vagus nerve activity might facilitate increased cytokine levels and worsen disease. A covariance analysis was performed to correct for respiratory influences on HF power. There remained a statistical significant correlation between HF power vs. HMGB1 (P < 0.01) and HF power vs. DAS-28 (P < 0.01). Including healthy controls in the analysis using the DAS-28 formula, the score correlated significantly to HMGB1 serum levels (rho = 0.83, P < 0.0001) (Figure 3b). Within the RA subjects alone however, the DAS-28 did not correlate to HMGB1 levels.
Recent evidence indicates an essential role of the vagus nerve in suppressing cytokine expression during inflammation (11–16). Cytokine expression in human macrophages is attenuated through the interaction of the principle vagus nerve neurotransmitter, acetylcholine, and the α7nAChR subunit located on cytokine expressing cells (12,13). Stimulating the vagus nerve either by electrical or pharmacological methods improves survival in animal models of inflammation (14). Administration of cholinergic agonists inhibited HMGB1 release and improved survival from infection in vivo by inhibiting NF-κB signaling through an α7nAChR dependent mechanism (15). We and others have suggested previously that decreased activity in the cholinergic anti-inflammatory pathway may facilitate excessive cytokine expression in the development and progression of inflammatory diseases.
The presence of subclinical cardiovascular disease in RA has been described previously and may have contributed partly to the lower RR variability observed in this study (28,29). It is interesting to consider whether subclinical cardiovascular disease is the result of increased inflammation from decreased vagus nerve activity.
Although the present study design does not enable a determination of causality, in the future it should be possible to increase vagus nerve activity via biofeedback, vagus nerve stimulation, or other measures and determine whether these maneuvers can decrease HMGB1 levels and improve the disease.
Supported in part by grants from NIGMS, NCRR (M01RR018535), and the Dana Foundation. We thank Marlena Kern, RN for her significant contributions in patient recruitment for our study.
- Kvien TK. (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics.22:1–12.View ArticleGoogle Scholar
- Kobelt G, Lindgren P, Lindroth Y, Jacobson L, Eberhardt K. (2005) Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology. 44:1169–75.View ArticleGoogle Scholar
- Kvien TK, Uhlig T, Odegard S, Heiberg MS. (2006) Epidemiological aspects of rheumatoid arthritis; the sex ratio. Ann. N. Y. Acad. Sci. 1069:212–22.View ArticleGoogle Scholar
- Mutru O, Laakso M, Isomaki H, Koota K. (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. Br. Med. J. 290:1797–9.View ArticleGoogle Scholar
- Kokkola R et al. (2003) Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum. 48:2052–8.View ArticleGoogle Scholar
- Taniguchi N et al. (2003) High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 48:971–81.View ArticleGoogle Scholar
- Pullerits R et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48:1693–700.View ArticleGoogle Scholar
- Andersson U, Tracey KJ. (2004) HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum. Dis. Clin. North Am. 30:627–37.View ArticleGoogle Scholar
- Lotze MT, Tracey KJ. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5:331–42.View ArticleGoogle Scholar
- Wang H et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–51.View ArticleGoogle Scholar
- Tracey KJ. (2002) The inflammatory reflex. Nature. 420:853–9.View ArticleGoogle Scholar
- Borovikova LV et al. (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 405:458–62.View ArticleGoogle Scholar
- Wang H et al. (2003) Nicotinic acetylcholine receptor α7 receptor is an essential regulator of inflammation. Nature. 421:384–8.View ArticleGoogle Scholar
- Bernik TR et al. (2002) Pharmacological stimulation of the cholinergic anti-inflammatory pathway. J. Exp. Med. 195:781–8.View ArticleGoogle Scholar
- Wang H et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10:1216–21.View ArticleGoogle Scholar
- Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. (2003) The cholinergic anti-inflammatory pathway: a missing link in neuromodulation. Mol. Med. 9:125–34.View ArticleGoogle Scholar
- Arnett FC et al. (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315–24.View ArticleGoogle Scholar
- Fransen J, Stucki G, van Riel P. (2003) Rheumatoid arthritis measures. Arthritis Rheum. 49:S214–24.View ArticleGoogle Scholar
- (1996) Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 93:1043–65.Google Scholar
- Song HS, Lehrer PM. (2003) The effects of specific respiratory rates on heart rate and heart rate variability. Appl Psychophysiol. Biofeedback. 28:13–23.View ArticleGoogle Scholar
- Akselrod S et al. (1981) Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. Science. 213:220–2.View ArticleGoogle Scholar
- Pomeranz B et al. (1985) Assessment of autonomic function in humans by heart rate spectral analysis. Am. J. Physiol. 248:151–3.Google Scholar
- Saul JP et al. (1991) Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am. J. Physiol. 261:1231–45.Google Scholar
- Taylor JA, Carr DL, Myers CW, Eckberg DL. (1998) Mechanisms underlying very-low-frequency RR-interval oscillations in humans. Circulation 98:547–55.View ArticleGoogle Scholar
- Evrengul H et al. (2004) Heart rate variability in patients with rheumatoid arthritis. Rheumatol. Int. 24:198–202.View ArticleGoogle Scholar
- Louthrenoo W, Ruttanaumpawan P, Aramrattana A, Sukitawut W. (1999) Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. QJM. 92:97–102.View ArticleGoogle Scholar
- Gonzalez-Juanatey C et al. (2003) Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine. 82:407–13.View ArticleGoogle Scholar
- Park YB et al. (2002) Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 46:1714–9.View ArticleGoogle Scholar